BRInging the Diabetes Prevention Program to GEriatric Populations
Launched by NYU LANGONE HEALTH · Dec 8, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "BRInging the Diabetes Prevention Program to GEriatric Populations," is studying how to help older adults reduce their risk of developing diabetes. Specifically, it aims to compare two ways of delivering a program designed to prevent diabetes: one that takes place in person and another that is delivered through telehealth (using phone or video calls). The goal is to see which method works better for older individuals aged 65 and over who have prediabetes, a condition that increases the risk of developing type 2 diabetes.
To participate in this study, you need to be at least 65 years old, diagnosed with prediabetes, and have a body mass index (BMI) of 30 or higher. You should also be able to speak English and have a primary care provider at NYU Langone Health. Participants will receive support in making healthy lifestyle changes through either in-person sessions or virtual meetings. The trial is currently recruiting, and it promises to offer valuable insights into how best to support older adults in managing their health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women aged 65 years and older
- • Diagnosis of pre-diabetes (A1c between 5.7-6.4%, fasting glucose between 100-125 mg/dL, or oral glucose tolerance test between 140-199 mg/dL within past 12 months)
- • BMI of greater than or equal to 30
- • English-speaking
- • Under the care of a Primary care provider (PCP) in the NYU Langone Health system
- • Able to travel to NYU Langone for in-person evaluations
- • Access to a telephone
- • Informed consent
- Exclusion Criteria:
- • Prevalent diabetes or end-stage renal disease
- • Prior participation in the Diabetes Prevention Program
- • A documented current history of active psychosis or other cognitive issues via International Classification of Diseases (ICD) -10 codes
- • Taking FDA-approved weight loss medications
- • PCP stating that patient should not participate
- • Inability to communicate due to severe, uncorrectable hearing loss or speech disorder
- • Severe visual impairment that precludes completion of assessments and/or intervention
About Nyu Langone Health
NYU Langone Health is a premier academic medical center located in New York City, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, NYU Langone Health integrates cutting-edge scientific inquiry with patient-centered care, striving to develop new therapies and improve health outcomes across a wide range of medical conditions. The institution is dedicated to fostering collaboration among researchers, clinicians, and patients, ensuring rigorous adherence to ethical standards and regulatory guidelines in all clinical research initiatives. By leveraging its extensive resources and expertise, NYU Langone Health aims to contribute significantly to the advancement of medical knowledge and the enhancement of patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Jeannette M Beasley, PhD, RDN
Principal Investigator
NYU Langone Health
Joshua Chodosh, MD, MHS
Principal Investigator
NYU Langone Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials